Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 4/2022

12-04-2021 | Acetazolamide | Original Article

An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection

Authors: Wen Zhou, Bin Zhang, Keyu Fan, Xiaojian Yin, Jinfeng Liu, Shaohua Gou

Published in: Cardiovascular Drugs and Therapy | Issue 4/2022

Login to get access

Abstract

Purpose

Hypoxic microenvironment plays a vital role in myocardial ischemia injury, generally leading to the resistance of chemotherapeutic drugs. This induces an intriguing study on mechanism exploration and prodrug design to overcome the hypoxia-induced drug resistance.

Methods

In this study, we hypothesized that the overexpression of carbonic anhydrase 9 (CAIX) in myocardial cells is closely related to the drug resistance. Herein, bioinformatics analysis, gene knockdown, and overexpression assay certificated the correlation between CAIX overexpression and hypoxia. An original aspirin-containing CAIX inhibitor AcAs has been developed.

Results

Based on the downregulation of CAIX level, both in vitro and in vivo, AcAs can overcome the acquired resistance and more effectively attenuate myocardial ischemia and hypoxia injury than that of aspirin. CAIX inhibitor is believed to recover the extracellular pH value so as to ensure the stable effect of aspirin.

Conclusion

Results indicate great potential of CAIX inhibitor for further application in myocardial hypoxia injury therapy.
Appendix
Available only for authorised users
Literature
1.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2019;72(18):2231–64.CrossRef
2.
Sharma A, Arambula JF, Koo S, Kumar R, Singh H, Sessler JL, et al. Hypoxia-targeted drug delivery. Chem Soc Rev. 2019;48(3):771–813.CrossRef
3.
Lan GX, Ni KY, Xu ZW, Veroneau SS, Song Y, Lin WB. Nanoscale metal-organic framework overcomes hypoxia for photodynamic therapy primed cancer immunotherapy. J Am Chem Soc. 2018;140(17):5670–3.CrossRef
4.
Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393(10186):2155–67.CrossRef
5.
Ridker PM. Should aspirin be used for primary prevention in the post-statin era? N Engl J Med. 2018;379(16):1572–4.CrossRef
6.
Chen J, Luo HL, Liu Y, Zhang W, Li HX, Luo T, et al. Oxygen-self-produced nanoplatform for relieving hypoxia and breaking resistance to sonodynamic treatment of pancreatic cancer. ACS Nano. 2017;11(12):12849–62.CrossRef
7.
Liu JN, Bu WB, Shi JL. Chemical design and synthesis of functionalized probes for imaging and treating tumor hypoxia. Chem Rev. 2017;117(9):6160–224.CrossRef
8.
Berk M, Dean D, Drexhage H, McNeil JJ, Moylan S, O’Neil A, et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. 2013;11(1):74.CrossRef
9.
Guirguis-Blake JM, Evans CV, Senger CA, O’Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the US preventive services task force. Ann Intern Med. 2016;164(12):804–13.CrossRef
10.
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–18.CrossRef
11.
Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res. 2020;117(1):74–84.CrossRef
12.
Semenza GL. Mechanisms of disease oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365(10):537–47.CrossRef
13.
Cao Q, Zhou DJ, Pan ZY, Yang GG, Zhang H, Ji LN, et al. CAIXplatins: highly potent Pt(IV) prodrugs selectively against hypoxic tumors via microenvironment and metabolism regulation. Angew Chem Int Edit. 2020;59(42):18556–62.CrossRef
14.
Cui J, Zhang Q, Song Q, Wang HR, Dmitriev P, Sun MY, et al. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma. Neuro-Oncology. 2019;21(11):1436–46.CrossRef
15.
John A, Sivashanmugam M, Natarajan SK, Umashankar V. Computational modeling of novel inhibitory peptides targeting proteoglycan like region of carbonic anhydrase IX and in vitro validation in HeLa cells. J Biomol Struct Dyn. 2020;38(7):1995–2006.CrossRef
16.
Jung HS, Han J, Shi H, Koo S, Singh H, Kim HJ, et al. Overcoming the limits of hypoxia in photodynamic therapy: a carbonic anhydrase IX-targeted approach. J Am Chem Soc. 2017;139(22):7595–602.CrossRef
17.
Scheibe RJ, Gros G, Parkkila S, Waheed A, Grubb JH, Shah GN, et al. Expression of membrane-bound carbonic anhydrases IV, IX, and XIV in the mouse heart. J Histochem Cytochem. 2006;54(12):1379–91.CrossRef
18.
Vargas LA, Pinilla OA, Diaz RG, Sepulveda DE, Swenson ER, Perez NG, et al. Carbonic anhydrase inhibitors reduce cardiac dysfunction after sustained coronary artery ligation in rats. Cardiovasc Pathol. 2016;25(6):468–77.CrossRef
19.
Orlowski A, De Giusti VC, Morgan PE, Aiello EA, Alvarez BV. Binding of carbonic anhydrase IX to extracellular loop 4 of the NBCe1 Na+/HCO3- cotransporter enhances NBCe1-mediated HCO3- influx in the rat heart. Am J Physiol-Cell Ph. 2012;303(1):C69–80.CrossRef
20.
Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 2004;64(17):6160–5.CrossRef
21.
Takov K, He ZH, Johnston HE, Timms JF, Guillot PV, Yellon DM, et al. Small extracellular vesicles secreted from human amniotic fluid mesenchymal stromal cells possess cardioprotective and promigratory potential. Basic Res Cardiol. 2020;115(3):26.CrossRef
22.
He Y, Zhou LY, Fan ZQ, Liu SK, Fang WJ. Palmitic acid, but not high-glucose, induced myocardial apoptosis is alleviated by N-acetylcysteine due to attenuated mitochondrial-derived ROS accumulation-induced endoplasmic reticulum stress. Cell Death Dis. 2018;9(5):568.CrossRef
23.
Zhao YP, Wang F, Jiang W, Liu JF, Liu BL, Qi LW, et al. A mitochondrion-targeting tanshinone IIA derivative attenuates myocardial hypoxia reoxygenation injury through a SDH-dependent antioxidant mechanism. J Drug Target. 2019;27(8):896–902.CrossRef
24.
Levey AS, Stevens LA, Schmid CH, Zhang YP, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRef
25.
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding fee energy function. J Comput Chem. 1998;19(14):1639–62.CrossRef
26.
Wan F, Peng QQ, Liu JF, Alolga RN, Zhou W. A novel ferulic acid derivative attenuates myocardial cell hypoxia reoxygenation injury through a succinate dehydrogenase dependent antioxidant mechanism. Eur J Pharmacol. 2019;856:172417.CrossRef
27.
Osadchii OE. Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev. 2007;12:66–86.CrossRef
28.
Allawadhi P, Khurana A, Sayed N, Kumari P, Godugu C. Isoproterenol-induced cardiac ischemia and fibrosis: Plant-based approaches for intervention. Phytother Res. 2018;32(10):1908–32.CrossRef
29.
Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177–85.CrossRef
Metadata
Title
An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection
Authors
Wen Zhou
Bin Zhang
Keyu Fan
Xiaojian Yin
Jinfeng Liu
Shaohua Gou
Publication date
12-04-2021
Publisher
Springer US
Keyword
Acetazolamide
Published in
Cardiovascular Drugs and Therapy / Issue 4/2022
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07182-2

Other articles of this Issue 4/2022

Cardiovascular Drugs and Therapy 4/2022 Go to the issue

Original Article

Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients

Original Article

A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology

Original Article

A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions

Original Article

Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines

Review Article

Cilostazol: a Review of Basic Mechanisms and Clinical Uses

Original Article

Association of Low Body Weight with Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban—J-ELD AF Registry Subanalysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits